



8 February 2023

Shareholder Update



Acquisition of Omni Innovation Pty Limited Completed

Myopharm Limited has recently completed the acquisition of Omni Innovation Pty Limited and wish to thank existing and new Shareholders for their support. The Omni Innovation Pty Ltd acquisition and intellectual IP handover took place 15th December 2022.

Myopharm continues to assess and execute upon growth opportunities associated with new product launches both in Australia and the overseas markets that develop and support global market access. We are preparing for a period of significant activity and growth and look forward to updating Shareholders.

We appreciate your continuing involvement in Myopharm.

Regards

For further information please contact:

Karinza Phoenix

Myopharm

Executive Chair & Chief Executive Officer

kphoenix@myopharm.com

Investor Enquiries

Investor@myopharm.com